Skip to Main Content

A plan to expand the use of Acadia Pharmaceuticals’ only approved medicine to cover the treatment of patients with schizophrenia was dealt a setback on Monday with the failure of a late-stage clinical trial, the company said.

The Acadia drug, called Nuplazid, failed to improve the overall symptoms of schizophrenia compared with a placebo. The Phase 3 study enrolled nearly 400 schizophrenia patients with moderate to severe psychotic symptoms inadequately controlled by currently approved drugs. 


Nuplazid, which is also known by its scientific name pimavanserin, is currently approved to treat psychosis related to Parkinson’s disease. The study, called ENHANCE, was Acadia’s first effort to expand the use of Nuplazid into a related indication. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.